• Klaria’s board extended subscriptions for its rights issue of units of up to SEK 147.6 million to November 6, 2026.
• Trading in unit rights will remain open through November 3, 2026, following the subscription extension.
• Additional subscription commitments without preferential rights total approximately SEK 2.2 million, with no compensation payable.
• These commitments fall within the existing guarantee structure totaling approximately SEK 111.1 million, covering 75.3% of the rights issue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klaria Pharma Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 202610220709BITN____UKPR__SV_20261022-BIT-8552-0) on October 22, 2026, and is solely responsible for the information contained therein.